Vera Therapeutics Inc (VERA) Stock Forecast & Price Target
Vera Therapeutics Inc · NASDAQ
$35.17-0.28 (-0.79%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Vera Therapeutics Inc, 8 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $43.00 to $125.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $81.57 sits 132% above the current $35.17. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.54 next quarter toward $-3.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy889%
Hold111%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Vera Therapeutics Inc.
As of Jul, 8 of 9 firms rate VERA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VERA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.54
Range $-1.79 – $-1.23 · 7 analysts · +22% YoY
Next period, 7 analysts expect Vera Therapeutics Inc to earn $-1.54 a share (range $-1.79 – $-1.23), versus $-1.26 a year earlier. Full-year consensus is $-6.21, growing to $-3.86 the year after.
REVENUE · NEXT QUARTER
$6.0M
Range $0 – $16.0M · 7 analysts
Revenue is expected to reach $6.0M (range $0 – $16.0M). Full-year consensus is $32.1M, rising to $261.1M next year.
Top analysts covering Vera Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VERA.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$86.00+144.5% to target
Overall win rate
46%
+ Follow
#2
Laura Chico
Wedbush · Rank #122
Hold
$43.00+22.3% to target
Overall win rate
40%
+ Follow
#3
Arthur He
HC Wainwright & Co. · Rank #150
Buy
$125.00+255.4% to target
Overall win rate
48%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #177
Buy
$65.00+84.8% to target
Overall win rate
38%
+ Follow
#5
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #232
Buy
$100.00+184.3% to target
Overall win rate
34%
+ Follow
VERA stock forecast FAQ
What is VERA's average 12-month price target?+
The 7 analysts with a live target average $81.57 for Vera Therapeutics Inc over the next 12 months, ranging from a $125.00 high to a $43.00 low.
Is VERA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 8 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VERA?+
The Street-high target is $125.00 (HC Wainwright & Co.), and the Street-low is $43.00 (Wedbush). The average of all 7 active targets is $81.57.
How many Wall Street analysts cover VERA?+
9 analysts have an active rating on Vera Therapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering VERA?+
Among analysts who currently cover VERA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $86.00 target.
What is Vera Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.54 per share (range $-1.79 – $-1.23) across 7 analysts. Full-year EPS is projected at $-6.21, rising to $-3.86 the following year.
How much revenue is Vera Therapeutics Inc expected to report next quarter?+
Consensus revenue is $6.0M (range $0 – $16.0M). Full-year revenue is projected at $32.1M, growing to $261.1M next year.
Have analysts been upgrading or downgrading VERA lately?+
As of Jul, 8 of 9 firms rate VERA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VERA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
